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Aim: To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophos-
phamide as primary systemic treatment in locally advanced breast cancer.
Patients and Methods: The activity and safety of intravenous pegylated liposomal doxorubicin 20mg sqm1
biweekly for eight courses in combination with metronomic cyclophosphamide 50 mg day1 orally were
evaluated in 29 patients with locally advanced breast cancer who were not suitable to receive a standard
chemotherapy due to age or co-morbidities or who asked for a regimenwith low incidence of toxic effects
irrespective of age.
Results: The rate of breast-conserving surgery was 44.8%. Eighteen patients (62.1%) achieved a partial
response (including one pathological complete response), 10 (34.5%) a stable disease and one patient
experienced a progressive disease. Treatment was well tolerated, with no grade 4 toxicities, and with
grade 3 skin toxicity in three patients and handefoot syndrome in four patients.
Conclusion: The regimen was well tolerated but with limited activity in the preoperative setting. Other
options (e.g., endocrine therapy in estrogen receptor -positive disease) should be considered in locally
advanced breast cancer patients who are not suitable to receive a standard chemotherapy.
 2011 Elsevier Ltd. All rights reserved.1,2Introduction
Anthracyclines are among the most widely used agents in the
treatment of early and advanced breast cancer. Doxorubicin-based
regimens have demonstrated beneﬁts in terms of response rate,
time to disease progression and overall survival. Despite its excel-
lent antitumour activity, conventional doxorubicin has a relatively
low therapeutic index, and its use is limited by the development of
myelosuppression, alopecia, nausea and vomiting, stomatitis andcology, Via Ripamonti 435,
2 57489571.
asqua).
All rights reserved.cumulative cardiotoxicity. The use of conventional doxorubicin is
also not generally recommended in patients with greater risks of
developing cardiac toxicity, such as those with pre-existing cardiac
disease, history of mediastinal irradiation and the elderly.3,4
Pegylated liposomal doxorubicin (PLD) is a formulation of
doxorubicin in polyethylene glycol-coated liposomes with a pro-
longed circulation time and speciﬁc accumulation in tumour
tissues, accounting for the much lower toxicity shown by PLD in
comparison to free doxorubicin in terms of cardiotoxicity, vesicant
effects, nausea, vomiting, alopecia and myelotoxicity.2,5e7 Typical
forms of toxicity associated to PLD are acute infusion reaction,
mucositis and palmar-plantar erythrodysesthesia, which occur
especially at high doses or short dosing intervals.8 Although the
single maximum tolerated dose (MTD) of PLD is actually lower than
S. Dellapasqua et al. / The Breast 20 (2011) 319e323320that of conventional doxorubicin, the cumulative MTD dose of PLD
may be substantially greater than that of free doxorubicin.9
Metronomic chemotherapy refers to the chronic administration
of low doses of cytotoxic drugs at close, regular intervals, with an
effect on tumour cells and particularly on endothelial cells.10
Several common anticancer agents have been shown to have
anti-angiogenic activity. Chronically administered low-dose cyclo-
phosphamide produces apoptosis of endothelial cells in the tumour
microvasculature with a compromised repairing process, therefore
inducing a prolonged anti-angiogenic effect.11 We previously
demonstrated the antitumour activity of oral low-dose cyclophos-
phamide and methotrexate delivered as metronomic chemo-
therapy in metastatic breast cancer.12
Preliminary results of a randomised phase III study (SWOG
0012) comparing standard intravenous (i.v.) doxorubicin þ
cyclophosphamide with weekly doxorubicin and daily oral low-
dose cyclophosphamide, both followed by weekly paclitaxel for
primary therapy of locally advanced and inﬂammatory breast
cancer, indicated a signiﬁcantly higher activity in terms of clinical
partial responses (PRs) for the continuous therapy.13
We conducted a phase II trial to evaluate the safety and activity
of the association of PLD and metronomic cyclophosphamide in
patients with locally advanced breast cancer who were not suitable
to receive a standard chemotherapeutic treatment due to age or co-
morbidities or who asked for a regimenwith low incidence of toxic
effects, irrespective of age.Patients and methods
Patients
Patients with stage IIeIII (T2-4a-d, N0-3 M0) breast cancer, aged
66 years or older, or not candidates to more intensive chemo-
therapy regimens due to co-morbidities or patients who asked for
a regimen with a low incidence of toxicity irrespective of age,
consecutively admitted at the Department of Medicine of the
European Institute of Oncology from May 2007 to December 2009
were enrolled in this phase II study.
A tru-cut biopsy was performed for diagnosis and for assess-
ment of biological characteristics of the tumour. Investigations
(chest X-ray, abdomen ultrasound, bone scan and/or ﬂudeox-
yglucose (18F)-positron emission tomography (FDG-PET)) were
performed to exclude distant metastases and blood tests were
performed to assess bone marrow, renal and hepatic function.
Cardiac functionwas assessed at baseline by electrocardiogram and
echocardiography. A left ventricular ejection fraction 55% and no
impairment of ventricular kinesis were required for study enrol-
ment. Eligibility criteria also included Eastern Cooperative
Oncology Group (ECOG) performance status 0e2, measurable
lesions, white blood cells 3000 mme3, platelets 100 000 mme3,
aspartate aminotransferase and alanine aminotransferase 2.5 
upper limit of normal and bilirubin 1.5 mg dle1. Written informed
consent was obtained from all patients and the protocol was
approved by the Ethical Committee of the European Institute of
Oncology.Treatment
PLD (Caelyx) was administered intravenously at the dose of
20 mg me2 once every 2 weeks for eight courses. Caelyx was
provided at no cost by Schering Plough. Cyclophosphamide
(Endoxan) was administered at the dose of 50 mg day1 orally for
16 weeks in a metronomic schedule. Cyclophosphamide was
commercially available at no cost for patients.A central venous catheter (CVC) in the subclavian or in the
jugular vein contralateral to the site of the tumour was implanted
in all patients before starting chemotherapy.
Deﬁnitive surgery (breast-conserving surgery or mastectomy,
with either sentinel lymph node biopsy or complete axillary lymph
node dissection) was performed 4 weeks after the eight courses of
Caelyx. Radiotherapywas indicated in patients undergoing breast-
conserving surgery and in patients with T4 tumours.Response criteria
Tumour was evaluated at baseline by physical measurement
with calliper of the two largest diameters and by means of
mammography and ultrasound. Patients underwent a physical
examination (including measurement of the tumour’s two largest
diameters with a calliper) every 2 weeks, before each chemo-
therapy administration. After four and eight cycles, patients also
had mammography and ultrasound breast examination to assess
response. Clinical responses were evaluated according to both
radiological (breast ultrasound or mammography) and clinical
evaluation, by measuring the largest diameters of the tumour and
were graded according to standard Response Evaluation Criteria In
Solid Tumors (RECIST) criteria.14 In inﬂammatory breast cancer,
clinical response was deﬁned as the disappearance of erythema,
oedema and decreased swelling of the breast at physical
examination.
Patients with stable disease (SD), partial response or complete
response after four courses qualiﬁed as candidates to receive four
more courses of therapy. Pathological complete responses (pCRs)
were evaluated according to Kuerer et al.15 A pCR was deﬁned as
a total disappearance of invasive tumour either in the breast or in
the axilla; the presence of intraductal carcinoma qualiﬁed for pCR.
Estrogen receptor (ER) and progesterone receptor (PgR) status,
assessment of the proliferative activity (percentage of Ki-67-
stained cells) and overexpression of HER2 were determined on
core biopsies obtained for diagnosis, as previously published.16
The results were recorded as the percentage of immunoreactive
cells over at least 2000 neoplastic cells. Steroid hormone receptor
status was classiﬁed as negative, poor (ER 1e9% of the cells) or
positive (ER and PgR >10% of the cells). As for Ki-67 labelling
index, we considered the value of 20% as a cut-off in dis-
tinguishing tumours with low (<20%) and high (20%) prolifer-
ative fraction. The value of 20% was selected based on previous
data from our group indicating that a value of Ki-67  20%
signiﬁcantly correlated with higher response rate to preoperative
chemotherapy.16 HER2 status was deﬁned at immunohisto-
chemistry (IHC) as negative (absent or faint and partial staining
in >10% of cells ¼ 1þ) and equivocal (faint and complete staining
in >10% of cells ¼ 2þ). In the latter cases, ﬂuorescence in situ
hybridisation (FISH) was performed to assess the ampliﬁcation of
the HER2 gene.Toxicity
Patients were assessed for toxicity every 2 weeks, before each
chemotherapy administration. Toxicity was recorded and classiﬁed
according to the National Cancer Institute (NCI) Common Termi-
nology Criteria for Adverse Events (CTCAE) version 3.0.17
Treatment was postponed by 1 week if the blood count on day
15 showed a neutrophil count <1000 mme3 and/or platelet count
was <100 000 mme3. In case of febrile neutropenia, or anaemia,
mucositis, hand and foot syndrome, gastrointestinal and
biochemical toxicity grade 2, a dose reduction by 25% of the related
drug was performed.
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The principal end points of the study were (a) clinical response
rate (complete and partial) according to RECIST criteria and (b) pCR.
A secondary end point was the assessment of the tolerability of PLD
in a homogeneous population of naive elderly patients.
In a previous study of primary therapy in endocrine-responsive
postmenopausal patients, we observed 50% clinical responses
(partial þ complete) and 6% pCRs. If we consider 15% pathological
complete response (pCR) rate to induction chemotherapy as
acceptable and 3% as unacceptable, in a two-stage minimax design
with 10% signiﬁcance level and 80% power, we needed to enrol 18
patients in theﬁrst stage; if none achieved a pCR, the studywas to be
closed for lack of activity. If one ormore patients achieved a pCR, the
study proceeded with the enrolment of the other 10 patients (for
a total of 28). If overall three or more patients yielded a pCR, it could
be assumed that a success rate of 15% was possible. Considering
a drop-out of 10%, we planned to recruit 30 patients within 2 years.Results
FromMay 2007 to December 2009, 29 patients were enrolled in
this phase II trial. All patients were evaluable for clinical response,
pathological response and toxicity.Table 1
Patients and tumor characteristics at baseline.
Characteristic N %
Enrolled 29
Evaluable for clinical response 29 100.0
Evaluable for pathological response 29 100.0
Evaluable for toxicity 29 100.0
Age, years
Median 54
Range 33e76
Menopausal status
Premenopausal 13 44.8
Postmenopausal 16 55.2
Clinical Tumor Size
2 17 58.6
3 8 27.6
4b 2 6.9
4d 2 6.9
Clinical Nodal Status
0 9 31.0
1 19 65.5
2 0 e
3 1 3.4
ER status
Negative 3 10.3
1e9% 0 e
 10% 26 89.7
PgR status
Negative 8 27.6
1e9% 5 17.2
 10% 16 55.2
Ki-67
< 20% 9 31.0
 20% 20 69.0
HER2
Absent 22 75.9
1þ 6 20.7
2þ 0 e
3þ 1 3.4
Grading
1 0 e
2 13 44.8
3 11 37.9
NA 5 17.2
NA: Not available.Patients and tumour characteristics at baseline and at ﬁnal
surgery are summarised in Table 1. Median agewas 54 years (range:
33e76 years). Thirteen patients were premenopausal, 16 patients
were postmenopausal, with six patients 66 years or older at the
time of study entry (so-called ‘elderly patients’).
Most patients were diagnosed with a clinical T2 (n ¼ 17, 58.6%)
or T3 (n¼ 8, 27.6%) disease, two patients had a T4b tumour and two
patients had an inﬂammatory disease (T4d). Nearly one-third of the
patients (n¼ 9, 31.0%) did not have clinically involved lymph nodes
at baseline, while two-thirds (n ¼ 19, 65.5%) had clinical N1 stage,
with one patient with cN3 stage.
Most patients had an endocrine-responsive tumour at baseline
(ER positive, n¼ 26, 89.7%; PgR positive, n¼ 16, 55.2%). HER2 status
was negative in 28 (96.6%) patients. Most tumours (n ¼ 20, 69.0%)
were classiﬁed as highly proliferating (Ki-67  20%) at baseline.
Surgery was performed in all patients. Thirteen patients
underwent a breast-conserving procedure after preoperative
treatment, 13 had a mastectomy, three patients underwent surgery
for bilateral disease, with bilateral mastectomy in one case. Six
patients underwent sentinel node biopsy only, with the majority of
patients undergoing an axillary clearance.
All patients were evaluable for clinical response (Table 2).
Overall, 18 patients (62.1%; 95% conﬁdence interval (CI),
42.4e78.7%) had a PR, of whom one patient achieved a pCR (3.4%;
95%CI, 0.09e17.8%), 10 patients (34.5%) had an SD and one patient
(3.4%) had a progression of disease (PD). No conclusion could be
drawn on the activity of the treatment in different tumour subsets,
since ER-negative patients constituted only about 10% of the total
number of patients.
Among patients with an inﬂammatory tumour (n ¼ 2), one
patient had a PR and one patient had an SD. Both T4d tumours were
endocrine-responsive, as was the tumour which progressed.
Median number of treatment cycles was eight (range: 3e8).
Twenty-two patients (75.9%) completed the number of planned
cycles, while seven patients discontinued chemotherapy earlier
than planned: four patients due to skin toxicity/handefoot
syndrome (of these, one patient discontinued treatment after the
third, one patient after the fourth, one patient after the sixth and
one patient after the seventh cycle), two patients due to medical
decision (they both had an SD after four and six cycles, respectively,
and were proposed to anticipate surgical intervention) and oneTable 2
Response after treatment.
N %
Clinical Response
Complete response 0 e
Partial response 18 62.1
Stable disease 10 34.5
Progression 1 3.4
Pathological Tumor Size
x 1 3.4
is 0 e
0 1 3.4
1 6 20.7
2 13 44.8
3 8 27.6
4b 0 e
4d 0 e
Nodal Status at Surgery
0 8 27.6
1 6 20.7
2 6 20.7
3 9 31.0
Type of Surgery
Breast conserving surgery 13 44.8
Mastectomy 13 44.8
Bilateral surgery 3 10.4
Table 3
Toxicity.
Grade 1 Grade 2 Grade 3
N % N % N %
Anemia 1 3.4 0 e 0 e
Leukopenia 0 e 3 10.3 0 e
Neutropenia 0 e 1 3.4 0 e
Nausea 7 24.1 0 e 0 e
Vomiting 1 3.4 0 e 0 e
Diarrhea 1 3.4 0 e 0 e
Stipsis 5 17.2 1 3.4 1 3.4
Mucositis 5 17.2 2 6.9 0 e
Hand-foot syndrome 8 27.6 6 20.7 4 13.8
Folliculitis 1 3.4 0 e 0 e
Asthenia 5 17.2 0 e 0 e
Gastric Pain 2 6.9 1 3.4 0 e
Hepatic 2 6.9 3 10.3 0 e
Skin 11 37.9 3 10.3 3 10.3
Neurological 1 3.4 0 e 0 e
Conjunctivitis 1 3.4 0 e 0 e
Fever 1 3.4 0 e 0 e
Hitching 1 3.4 0 e 0 e
Pharyngitis 1 3.4 0 e 0 e
Otitis 1 3.4 0 e 0 e
Rhinitis 1 3.4 0 e 0 e
Alopecia 0 e 0 e 0 e
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tolerated, with no grade 4 and grade 3 toxicities mainly related to
handefoot syndrome (four patients, 14%) and skin toxicity (three
patients, 10%). Main toxicities are summarised in Table 3. Treatment
with Caelyx was delayed in eight and doses modiﬁed in 13
patients, while treatment with cyclophosphamide was delayed in
only four patients. Alopecia was not observed during treatment.
Discussion
Anthracyclines are usually prescribed in the preoperative
treatment for locally advanced and operable breast cancer,18 but
their limit resides in their low therapeutic index, especially for
cumulative cardiotoxicity. For this reason, current standard
chemotherapy regimens might not be adequate for patients in
whom the issue of safety is particularly relevant, such as elderly
patients or patients with co-morbidities. PLD has a favourable
safety proﬁle and comparable clinical activity as compared with
conventional doxorubicin; therefore, this drug may be suitable for
the treatment of elderly and/or frail patients and of patients who
refuse a standard anthracycline regimen because of possible
alopecia. The activity of PLD (50 mg sqme1) in combination with
full-dose oral cyclophosphamide (100 mg sqme1 days 1e14) every
28 days was shown to be active in advanced breast cancer, although
the toxicity proﬁle compared unfavourably with the i.v. adminis-
tration of cyclophosphamide. The results of the SWOG trial
provided the rationale for investigating intermittent i.v. bolus
administration of an anthracycline in combination with metro-
nomic oral cyclophosphamide. Studies on PLD in different tumours,
although insufﬁcient to deﬁne an ideal dose schedule, indicate that
lower doses (35 mg sqme1) are as effective as higher doses as long
as dose intensity is maintained at 10 mg sqme1 per week.19 We
have previously investigated the activity of this low-dose frequent
schedule, which mimics a metronomic administrationwith the aim
of increasing activity and lowering toxicity, in heavily pretreated
advanced breast cancer patients. We obtained a clinical beneﬁt
(deﬁned as objective responses þ SD lasting 24 weeks) in 33% of
patients, with a favourable toxicity proﬁle.
In the present study, the overall clinical response rate was 62.1%
(95%CI, 42.4e78.7%), with a pCR rate of 3.4% (95%CI, 0.09e17.8%).The small sample size, and in particular the small number of
patients with ER-negative tumours, did not allow to draw conclu-
sions on the activity of the treatment in different tumour subsets.
Limited data are available with PLD in the preoperative
setting. Preliminary data with the association of PLD and cyclo-
phosphamide have yielded a 73% clinical response rate.20 The
combination of PLD and weekly paclitaxel has yielded a clinical
response rate of 74% and a pCR rate of 8e9%.21,22 In a previous trial
conducted in our Institution, the combination of PLD with cisplatin
and continuous infusion ﬂuorouracil (CCF) for eight courses
provided a clinical response rate of 77.5%, whereas a pCR was
obtained in three patients (7.7%).23
In our trial, 14% of the patients had locally far advanced tumours
(T4b and T4d) which may partly account for the different outcomes
seen in this as compared to previous series. Most importantly, the
great majority (90%) of the patients included in this trial had an
endocrine-responsive tumour at baseline. The absence of hormone
receptors is generally recognised as the most powerful predictor of
pCR after primary chemotherapy16. In a recent retrospective
analysis of patients treated with preoperative chemotherapy at our
Institution, we obtained a 3.3% and 0% pCR rates in patients with
incomplete and highly endocrine-responsive tumours, respec-
tively.24 In the preoperative setting, inconclusive data are available
on the association of endocrine therapy with chemotherapy: the
combination did not show an improvement of pCR rate in pop-
ulations unselected for hormone receptor status; however, an effect
in proliferative rate decrease in patients with ER-positive tumours
has been shown.25e27 In a trial conducted in our Institution in
premenopausal women with endocrine-responsive locally
advanced tumours, we observed an increased clinical and patho-
logical response rate by the addition of Gonadotropin Releasing
Hormone (GnRH) analogue to chemotherapy as compared to
a historical control group treated with chemotherapy alone.28
Moreover, the presence of a speciﬁc histotype might be corre-
lated with the probability of response and with the outcome of
patients. Response to primary chemotherapy is lower in terms of
pCR (0e3%) in locally advanced invasive lobular carcinoma (ILC)
compared with invasive ductal carcinoma (IDC).29e31 In our series,
21 patients had a ductal inﬁltrating carcinoma, six a lobular inﬁl-
trating carcinoma and one a mucinous inﬁltrating carcinoma.
Inﬁltrating lobular and mucinous carcinomas are characterised by
signiﬁcantly higher expression of steroid hormone receptors when
compared with IDC, and this might have contributed to the lower
response to preoperative chemotherapy.
Treatment was well tolerated. No grade 4 toxicities were
observed. Treatment-related grade 3 toxicities were mostly asso-
ciated to cutaneous toxicity, in particular handefoot syndrome
(n ¼ 4, 13.8%) and skin toxicity (n ¼ 3, 10.3%). Cutaneous toxicity
was reversible after treatment discontinuation. There were no
severe or prolonged neutropenia or leucopoenia, and alopecia was
not observed in any of the patients treated in the trial.
In conclusion, the results from this phase II trial of preoperative
PLD in association with metronomic cyclophosphamide demon-
strate that this regimenwas well tolerated, although with a limited
activity in the preoperative setting. Other options, including
endocrine therapy, should be considered in ER-positive locally
advanced breast cancer in patients who are not suitable to receive
a standard preoperative chemotherapy. Due to its favourable
toxicity proﬁle, this regimen may be further studied in the meta-
static setting, especially in elderly patients or in patients who are
not suitable to receive a standard chemotherapy.
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